Dr. Nistor’s work is marked by scientific method, creativity, innovation, critical thinking, analysis, information synthesis and personal expression. The leadership promoted is based on integrity, ethical judgment, personal example, clear communication and skill transfer.
Education: medical school, residency program and practicing MD for 6 years followed by postdoctoral studies at University California Irvine. The medical and academic experience was followed by 15 years of research leadership in regenerative medicine (stem cells) and immunotherapy (cancer stem cells) as Vice President of R&D at California Stem Cell, Inc. from 2006, continued as Vice President for Research at Caladrius Biosciences (former NeoStem, Inc.) after acquisition to current date.
At California Stem Cell Inc, using the knowledge gained with the normal stem cells Dr. Nistor adopted modern principles of product development based on quality by design for autologous immunotherapy in cancer. Developed methods and reagents for rapid purification and expansion of tumor initiating cells (cancer stem cells); investigated patient serum factors that may reflect the treatment efficacy or disease progression in cancer, investigated genomic correlations of the immunotherapy treatment responders. Coordinated the development of new pipelines of cell products with application in research and clinic. Conducted the activities related to elucidation of mechanism of action in cancer immunotherapy using cancer stem cell antigens.
Dr. Nistor has filed multiple patents in the area of normal and cancer stem cells. The patents include compositions, reagents and methods suitable for cell-replacement therapies and cancer immunotherapies. As a Vice President for Research, actively participated with corporate legal office in patenting strategy and in pre-grant patent prosecution process for initial filings and multiple divisional and international filings.